ArriVent BioPharma (NASDAQ:AVBP) Shares Up 7% – Time to Buy?

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) rose 7% during mid-day trading on Thursday. The company traded as high as $11.61 and last traded at $11.6630. 161,376 shares were traded during mid-day trading, a decline of 79% from the average session volume of 753,010 shares. The stock had previously closed at $10.90.

Analysts Set New Price Targets

AVBP has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Thursday, October 15th. B. Riley Financial reduced their price objective on ArriVent BioPharma from $45.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Wall Street Zen raised ArriVent BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Truist Financial upped their target price on ArriVent BioPharma from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a report on Thursday, November 12th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Check Out Our Latest Stock Report on AVBP

ArriVent BioPharma Stock Performance

The firm has a market cap of $601.80 million, a PE ratio of -3.23 and a beta of 1.66. The stock has a 50 day simple moving average of $20.20 and a two-hundred day simple moving average of $26.23.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.80 million. Equities research analysts forecast that ArriVent BioPharma, Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Montanova Capital LLC increased its holdings in ArriVent BioPharma by 2.6% in the 2nd quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock worth $156,870,000 after acquiring an additional 114,448 shares in the last quarter. Hhlr Advisors LTD. acquired a new stake in shares of ArriVent BioPharma in the second quarter worth approximately $136,498,000. BlackRock Inc. acquired a new stake in shares of ArriVent BioPharma in the second quarter worth approximately $112,919,000. General Catalyst Group Management LLC purchased a new stake in shares of ArriVent BioPharma during the second quarter worth approximately $51,929,000. Finally, Goldman Sachs Group Inc. increased its position in shares of ArriVent BioPharma by 29.7% during the third quarter. Goldman Sachs Group Inc. now owns 1,107,094 shares of the company’s stock worth $33,523,000 after purchasing an additional 253,371 shares in the last quarter. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Featured Stories

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.